| アブストラクト | INTRODUCTION: Data on the burden of hypereosinophilic syndrome (HES) are limited. This study investigated the incidence and prevalence of HES using real-world data from patients in the United Kingdom. METHODS: Primary care data from the Clinical Practice Research Datalink were analyzed. The patients of interest were identified using medical codes specific for HES. Annual incidence rates and prevalence were estimated for the years 2010-2018 (inclusive) using patients observed for a minimum period of one year. RESULTS: Between 2010 and 2018, 93 patients were identified with HES. During the study period the incidence of HES ranged from less than 0.04, 95% confidence interval (CI) (0.01-0.07) to 0.17, 95% CI (0.10-0.26) per 100,000 person-years and the prevalence ranged from 0.15, 95% CI (0.10-0.25) to 0.89, 95% CI (0.74-1.09) cases per 100,000 persons. Sensitivity analyses varying the minimum observation period required to identify HES patients gave similar results. CONCLUSION: These results provide estimates of the burden of HES in the United Kingdom and indicate that whilst HES is a very rare disease, there is evidence that is increasingly being recorded in UK primary care. |
|---|
| ジャーナル名 | Immunity, inflammation and disease |
|---|
| Pubmed追加日 | 2021/7/23 |
|---|
| 投稿者 | Requena, Gema; Logie, John; Gibbons, Daniel C; Steinfeld, Jonathan; Van Dyke, Melissa K |
|---|
| 組織名 | Epidemiology, Value Evidence and Outcomes, Global R&D, GSK, London, UK.;Real World Analytics, Value Evidence and Outcomes, Global Medical, GSK, London,;UK.;Respiratory Research & Development, GSK, Collegeville, Pennsylvania, USA.;Epidemiology, Value Evidence and Outcomes, Global R&D, GSK, Collegeville,;Pennsylvania, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34293251/ |
|---|
